Fundamentals Overview
United Therapeutics Corporation is near the high of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
+27.2% upside vs price
Profitability
Risk (Beta)
0.75 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +27.2% upside vs price · Analyst grade: B+ · 3M vs S&P 500: +19% · 3M vs Healthcare sector: +25.8%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Current institutional positions: Buy: 14, Equal Weight: 8, Neutral: 2, Outperform: 4, Overweight: 2.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $734.42; current price is $577.58. That’s a +27.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 20.73 |
| DCF value (model) | $734.42 (27.2% upside) |
| PEG (TTM) | 1.77 |
| P/B (TTM) | 3.61 |
| P/S (TTM) | 7.95 |
| P/FCF (TTM) | 24.32 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 6.6 |
| Quick Ratio (TTM) | 6.28 |
| Cash Ratio (TTM) | 2.78 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 41.94% |
| Gross margin (TTM) | 87.92% |
| Operating margin (TTM) | 46.89% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for UTHR.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-04-10 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2026-03-31 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-31 |
| B of A Securities | maintain | Neutral | Neutral | 2026-03-31 |
| TD Cowen | maintain | Buy | Buy | 2026-03-30 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2026-03-23 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2026-03-12 |
| UBS | maintain | Buy | Buy | 2026-03-05 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-02-26 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-26 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2026-02-26 |
| TD Cowen | maintain | Buy | Buy | 2026-02-26 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-26 |
| UBS | maintain | Buy | Buy | 2026-01-06 |
| UBS | maintain | Buy | Buy | 2025-11-06 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-10-30 |
| RBC Capital | maintain | Outperform | Outperform | 2025-10-30 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-10-30 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-10-10 |
| UBS | maintain | Buy | Buy | 2025-09-29 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2025-09-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-09-05 |
| Oppenheimer | maintain | Outperform | Outperform | 2025-09-05 |
| UBS | maintain | Buy | Buy | 2025-09-04 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-09-03 |
| B of A Securities | maintain | Neutral | Neutral | 2025-09-02 |
| Jefferies | maintain | Buy | Buy | 2025-09-02 |
| UBS | maintain | Buy | Buy | 2025-08-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-07-31 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-07-31 |